Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3612 participants.
Also called NCT06756945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,612 participants
- Sponsor
- Registry
-
NCT06756945
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06756945. Randomized; double masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial
- Acronym
- LEAST
- Condition
- ST-elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
- Intervention (Drug)
- aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
- Lead sponsor
- Beijing Anzhen Hospital
Record details
- Record id
cardio:ct-nct06756945- Content hash
dd3db925d50d16a70ca5d1d8356fa8e3b0b028af49561ee9b154b6c8a35a4f42